Overstreet, Anne-Marie C.
Grayson, Bernadette E.
Boger, Antonia
Bakke, Danika
Carmody, Erin M.
Bales, Cayla E.
Paski, Shirley C.
Murphy, Stephen F.
Dethlefs, Christopher R.
Shannon, Kara J.
Adlaka, Katie R.
Wolford, Claire E.
Campiti, Vincent J.
Raghunandan, Christina V.
Seeley, Randy J.
Boone, David L.
Funding for this research was provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (F32HD68103)
National Institute of Diabetes and Digestive and Kidney Diseases (F32DK089719, DK056863, 1R21DK110263)
National Institute of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award (UL1 TR001108)
Rainin Foundation
Article History
Received: 19 November 2020
Accepted: 19 April 2021
First Online: 4 May 2021
Competing interests
: DLB owns Lumen Bio LLC, which has patents filed related to gastrokine-1 and obesity. DLB receives research support from Pfizer. R.J.S. receives research support from Ethicon Endo-Surgery/Johnson & Johnson, Novo Nordisk, Janssen/Johnson & Johnson, Medimmune, MedImmune, Kalyope and Sanofi. R.J.S. serves as a consultant for Ethicon Endo-Surgery/Johnson & Johnson, Novartis, Orexigen, Novo Nordisk, Daiichi Sankyo, Janssen/Johnson & Johnson, Paul Hastings Law Firm, Kallyope and Scohia. All other authors declare no conflicts.